Chest
Original ResearchInterstitial Lung DiseaseClinical Profile of Anti-PL-12 Autoantibody: Cohort Study and Review of the Literature
Section snippets
Materials and Methods
We performed a retrospective chart review of all anti-PL-12-positive patients at the following four tertiary care institutions: Medical University of South Carolina (MUSC); University of Pittsburgh Medical Center (UPMC); Johns Hopkins Medical Center (JHMC); and Brigham and Women's Hospital (BWH). Serologic testing was done at specialty laboratories by radio immunoprecipitation (IP) assay for MUSC and BWH. The sera at both UPMC and JHMC were analyzed by IP at university research laboratories. At
Results
Thirty-one patients with anti-PL-12 were identified (Table 2), as follows: UPMC, 14 patients; MUSC, 9 patients; JHMC, 5 patients; and BWH, 3 patients. The median age at diagnosis was 51 years (range, 22 to 87 years). There were 25 females (81%) and 16 African Americans (52%), 14 whites (45%), and 1 Hispanic patient (3%). Ninety percent had an underlying CTD. Ten patients (32%) had PM, 6 patients had DM (19%), and 5 patients (16%) had overlap syndromes with features of an IIM and a second CTD.
Discussion
The aminoacyl-tRNA synthetases are a group of ubiquitous cytoplasmic enzymes that play an important role in protein synthesis. Each cell has 20 different synthetases, one for each amino acid. The aminoacyl-tRNA synthetase enzyme recognizes its cognate amino acid, enabling correct sequencing within the polypeptide chain.5 Autoantibodies directed against these synthetases occur in the sera of 16 to 26% of adult patients with IIM and are considered specific to this disease.27 Anti-Jo-1, the first
References (33)
- et al.
A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis sine myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies
J Am Acad Dermatol
(2006) - et al.
A 34-year-old man presenting with gradual onset of shortness of breath and interstitial lung disease
Chest
(2008) - et al.
Interstitial lung disease with autoantibodies against aminoacyl-tRNA synthetases in the absence of clinically apparent myositis
Semin Arthritis Rheum
(1996) - et al.
Clinical manifestations in patients with antibody to PL-12 antigen (alanyl-tRNA synthetase)
Am J Med
(1990) - et al.
Polymyositis and interstitial lung disease in a patient with anti-Jo1 prototype
Am J Med
(1984) Immune manifestations of inflammatory muscle disease
Rheum Dis Clin North Am
(1994)- et al.
Autoantibodies in idiopathic inflammatory myopathy: an update on clinical and pathophysiological significance
Curr Opin Rheumatol
(2007) - et al.
Heterogeneity of precipitating antibodies in polymyositis and dermatomyositis: characterization of the Jo-1 antibody system
Arthritis Rheum
(1980) - et al.
The precipitating antibody to an acidic nuclear protein antigen, the Jo-1, in connective tissue diseases: a marker for a subset of polymyositis with interstitial pulmonary fibrosis
Arthritis Rheum
(1983) - et al.
Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes
Q J Med
(1990)
Humoral immunity in polymyositis/dermatomyositis
J Invest Dermatol
Polymyositis and dermatomyositis (second of two parts)
N Engl J Med
Interstitial lung disease in association with polymyositis-dermatomyositis: long-term follow-up CT evaluation in seven patients
Radiology
High-resolution CT findings of lung disease in patients with polymyositis and dermatomyositis
J Thorac Imaging
A cutaneous lesion associated with myositis
Ann Intern Med
Interstitial lung disease in polymyositis and dermatomyositis
Arthritis Rheum
Cited by (141)
Phenotypic Profiles Among 72 Caucasian and Afro-Caribbean Patients with Antisynthetase Syndrome Involving Anti-PL7 or Anti-PL12 Autoantibodies
2023, European Journal of Internal MedicineMyositis-associated interstitial lung disease
2023, Revista Colombiana de ReumatologiaSkin manifestations and autoimmune disturbances in dermatomyositis
2023, Translational Autoimmunity: Volume 6: Advances in Autoimmune Rheumatic DiseasesPossible future avenues for myositis therapeutics: DM, IMNM and IBM
2022, Best Practice and Research: Clinical RheumatologyPulmonary histopathology of interstitial lung disease associated with antisynthetase antibodies
2022, Respiratory Medicine
The authors have reported to the ACCP that no significant conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (www.chestjournal.org/site/misc/reprints.xhtml).